Alpha Cognition Inc. announced new preclinical data for ALPHA-1062, further supporting its development for the treatment of mild traumatic brain injury (mTBI). The study, supported by the US Department of Defense, demonstrated a notable reduction in indices of TBI-associated neuropathology following blast-induced mTBI.
The data revealed that ALPHA-1062 administration reduced brain levels of three toxic forms of Tau protein: pTau 217, pTau-S202/T205, and pTau 231. The reduction of these toxic pTau forms suggests a potential role for ALPHA-1062 in treating TBI and potentially mitigating the risk of later developing Alzheimer’s disease.
Additional benefits observed included reduced numbers of myeloid cells and astrocytes, consistent with decreased neuroinflammation, and an increase in nerve growth factor receptor expression in a dose-dependent manner. Alpha Cognition's next steps involve formulating ALPHA-1062 for sublingual administration and conducting a bridging pharmacokinetic study.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.